Chronic Myelogenous Leukemia - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Chronic Myelogenous Leukemia > What Your Doctor is Reading About Chronic Myelogenous Leukemia > Clinical Trials

Clinical Trials

1. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.

Author: Quintas-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Estrov Z; Giles F; Murgo A; Ladie N; Verstovsek S; Cortes J;
Institution: Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Journal: Cancer. 2007 Jan 15;109(2):248-55.
Abstract URL: Click here to view abstract

2. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

Author: Kantarjian H; Giles F; Wunderle L; Bhalla K; O'Brien S; Wassmann B; Tanaka C; Manley P; Rae P; Mietlowski W; Bochinski K; Hochhaus A; Griffin JD; Hoelzer D; Albitar M; Dugan M; Cortes J; Alland L; Ottmann OG;
Institution: Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX 77230-1402, USA. hkantarj@mdanderson.org
Journal: N Engl J Med. 2006 Jun 15;354(24):2542-51.
Abstract URL: Click here to view abstract

3. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Author: Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL;
Institution: Department of Leukemia, M.D. Anderson Cancer Center, Houston, USA.
Journal: N Engl J Med. 2006 Jun 15;354(24):2531-41.
Abstract URL: Click here to view abstract

4. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.

Author: Zaucha JM; Prejzner W; Giebel S; Gooley TA; Szatkowski D; Kalwak K; Wojnar J; Kruzel T; Balon J; Holowiecki J; Hellmann A;
Institution: Department of Hematology, Medical University of Gdansk, Gdansk, Poland. jzaucha@amg.gda.pl
Journal: Bone Marrow Transplant. 2005 Sep;36(5):417-24.
Abstract URL: Click here to view abstract

5. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.

Author: Bornhauser M; Kroger N; Schwerdtfeger R; Schafer-Eckart K; Sayer HG; Scheid C; Stelljes M; Kienast J; Mundhenk P; Fruehauf S; Kiehl MG; Wandt H; Theuser C; Ehninger G; Zander AR;
Institution: Medizinische Klinik und Poliklinik I, Universitatsklinikum Carl Gustav Carus, Dresden, Germany. martin.bornhaeuser@uniklinikum-dresden.de
Journal: Eur J Haematol. 2006 Jan;76(1):9-17.
Abstract URL: Click here to view abstract

6. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.

Author: Borthakur G; Kantarjian H; Daley G; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Faderl S; Sugrue M; Cortes J;
Institution: Department of Leukemia, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Journal: Cancer. 2006 Jan 15;106(2):346-52.
Abstract URL: Click here to view abstract

7. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation.

Author: Millot F; Guilhot J; Nelken B; Leblanc T; De Bont ES; Bekassy AN; Gadner H; Sufliarska S; Stary J; Gschaidmeier H; Guilhot F; Suttorp M;
Institution: Department of Hematology, CHU la Miletrie, Poitiers, France. f.millot@chu-poitiers.fr
Journal: Leukemia. 2006 Feb;20(2):187-92.
Abstract URL: Click here to view abstract

8. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naive, chronic-phase chronic myelogenous leukemia.

Author: Lipton JH; Khoroshko N; Golenkov A; Abdulkadyrov K; Nair K; Raghunadharao D; Brummendorf T; Yoo K; Bergstrom B;
Institution: Department of Medical Oncology, Princess Margaret Hospital, Toronto, ON, Canada. jeff.lipton@uhn.on.ca
Journal: Leuk Lymphoma. 2007 Mar;48(3):497-505.
Abstract URL: Click here to view abstract

9. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Author: Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P;
Institution: Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77230-1402, USA. hkantarj@mdanderson.org
Journal: Blood. 2007 Nov 15;110(10):3540-6. Epub 2007 Aug 22.
Abstract URL: Click here to view abstract

10. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.

Author: Olavarria E; Siddique S; Griffiths MJ; Avery S; Byrne JL; Piper KP; Lennard AL; Pallan L; Arrazi JM; Perz JB; O'Shea D; Goldman JM; Apperley JF; Craddock CF;
Institution: Department of Haematology, Imperial College, Hammersmith Hospital, London, UK.
Journal: Blood. 2007 Dec 15;110(13):4614-7. Epub 2007 Sep 19.
Abstract URL: Click here to view abstract

11. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.

Author: Cortes J; Quintas-Cardama A; Garcia-Manero G; O'Brien S; Jones D; Faderl S; Ebarb T; Giles F; Thomas D; Kantarjian H;
Institution: Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. jcortes@mdahderson.org
Journal: Cancer. 2007 Nov 1;110(9):2000-6.
Abstract URL: Click here to view abstract

12. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.

Author: Quintas-Cardama A; Kantarjian H; O'brien S; Borthakur G; Bruzzi J; Munden R; Cortes J;
Institution: Department of Leukemia and Department of Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. aquintas@mdanderson.org
Journal: J Clin Oncol. 2007 Sep 1;25(25):3908-14.
Abstract URL: Click here to view abstract

13. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.

Author: Cortes J; Jabbour E; Daley GQ; O'Brien S; Verstovsek S; Ferrajoli A; Koller C; Zhu Y; Statkevich P; Kantarjian H;
Institution: Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. jcortes@mdanderson.org
Journal: Cancer. 2007 Sep 15;110(6):1295-302.
Abstract URL: Click here to view abstract

14. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.

Author: Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K;
Institution: Division of Molecular Pathology, Institute of Medical and Veterinary Science, Adelaide, SA, Australia. susan.branford@imvs.sa.gov.au
Journal: Cancer. 2007 Aug 15;110(4):801-8.
Abstract URL: Click here to view abstract

15. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

Author: Cortes J; Rousselot P; Kim DW; Ritchie E; Hamerschlak N; Coutre S; Hochhaus A; Guilhot F; Saglio G; Apperley J; Ottmann O; Shah N; Erben P; Branford S; Agarwal P; Gollerkeri A; Baccarani M;
Institution: M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. jcortes@mdanderson.org
Journal: Blood. 2007 Apr 15;109(8):3207-13. Epub 2006 Dec 21.
Abstract URL: Click here to view abstract

16. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.

Author: Oki Y; Kantarjian HM; Gharibyan V; Jones D; O'brien S; Verstovsek S; Cortes J; Morris GM; Garcia-Manero G; Issa JP;
Institution: Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Journal: Cancer. 2007 Mar 1;109(5):899-906.
Abstract URL: Click here to view abstract

17. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party.

Author: Rosti G; Iacobucci I; Bassi S; Castagnetti F; Amabile M; Cilloni D; Poerio A; Soverini S; Palandri F; Rege Cambrin G; Iuliano F; Alimena G; Latagliata R; Testoni N; Pane F; Saglio G; Baccarani M; Martinelli G;
Institution: Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy.
Journal: Haematologica. 2007 Jan;92(1):101-5.
Abstract URL: Click here to view abstract

18. Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse.

Author: Ringhoffer M; Harsdorf S; Schmitt M; Wiesneth M; Zenz T; Stilgenbauer S; Greiner J; Dohner K; Marx M; Dohner H; Bunjes D;
Institution: Third Department of Medicine, University Hospital of Ulm, Ulm, Germany.
Journal: Br J Haematol. 2007 Jan;136(1):127-30.
Abstract URL: Click here to view abstract

19. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Author: Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA; Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
Institution: Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA. drukerb@ohsu.edu
Journal: N Engl J Med. 2006 Dec 7;355(23):2408-17.
Abstract URL: Click here to view abstract

20. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.

Author: Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhauser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T;
Institution: III. Med. Klinik, Johannes Gutenberg-University, Mainz; University of Ulm, II. Med. Klinik, Charite, Germany.
Journal: J Clin Oncol. 2005 Oct 20;23(30):7583-93.
Abstract URL: Click here to view abstract

21. Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia.

Author: Millot F; Guilhot J; Nelken B; Leblanc T; Leverger G; Bernard F; Gandemer V; Behard C; Berger C; Cornu G; Duchene S; Guilhot F;
Institution: Oncology Hematology, University Hospital, Poitiers, France. f.millot@chu-poitiers.fr
Journal: Pediatr Blood Cancer. 2006 Oct 15;47(5):555-9.
Abstract URL: Click here to view abstract

22. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.

Author: Issa, Jean-Pierre J; Gharibyan, Vazganush; Cortes, Jorge; Jelinek, Jaroslav; Morris, Gail; Verstovsek, Srdan; Talpaz, Moshe; Garcia-Manero, Guillermo; Kantarjian, Hagop M;
Institution: Department of Leukemia and Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. jpissa@mdanderson.org
Journal: J Clin Oncol 2005 Jun 10;23(17):3948-56. Epub 2005 May 9.
Abstract URL: Click here to view abstract

23. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies.

Author: Berger, U; Maywald, O; Pfirrmann, M; Lahaye, T; Hochhaus, A; Reiter, A; Hasford, J; Heimpel, H; Hossfeld, D K; Kolb, H-J; Loffler, H; Pralle, H; Queisser, W; Hehlmann, R;
Institution: III. Medizinische Universitatsklinik, Fakultat fur Klinische Medizin Mannheim, Universitat Heidelberg, 68305 Mannheim, Germany. ute.bergen@med3.ma.uni-heidelberg.de
Journal: Leukemia 2005 Jun;19(6):984-9.
Abstract URL: Click here to view abstract

24. In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study.

Author: Bonifazi, F; Bandini, G; Stanzani, M; Palandri, F; Giannini, B; Arpinati, M; Rosti, G; Baccarani, M;
Institution
Journal: Bone Marrow Transplant 2005 May;35(10):1025-6.

25. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.

Author: Marin, David; Kaeda, Jaspal S; Andreasson, Catharina; Saunders, Sue M; Bua, Marco; Olavarria, Eduardo; Goldman, John M; Apperley, Jane F;
Institution: Department of Haematology, Imperial College London at Hammersmith Hospital, London, United Kingdom.
Journal: Cancer 2005 May 1;103(9):1850-5.
Abstract URL: Click here to view abstract

26. Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment.

Author: Roberto, Latagliata; Massimo, Breccia; Ida, Carmosino; Chiara, Sarlo; Enrico, Montefusco; Marco, Mancini; Antonio, Chistolini; Rosa, De Cuia; Eleonora, Russo; Giacomo, Morano Salvatore; Francesca, Biondo; Antonio, Spadea; Franco, Mandelli; Giuliana, Alimena; Fiammetta, Natalino;
Institution: Dipartimento di Biotecnologie Umane ed Ematologia, Universita ""La Sapienza"" di Roma, Via Benevento 6-00161, Rome, Italy. rob.lati@libero.it
Journal: Leuk Res 2005 Mar;29(3):287-91.
Abstract URL: Click here to view abstract

27. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.

Author: Silver, R T;
Institution: The Leukemia and Myeloproliferative Disease Center, Division of Hematology-Oncology, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA. rtsilve@mail.med.cornell.edu
Journal: Leukemia 2005 Jan;19(1):39-43.
Abstract URL: Click here to view abstract